Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:55:56.930Z.
Calculation as of: 2026-10-06T22:55:56.930Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 953d1456faf84e3d3f88a5480ffc5766df2e412b5fda6c1fb2fa7c75cf2e613b
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | $329.37M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $324.76M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $322.71M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | N/A | 16.56 | 19.39 | 19.39 |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A | 0.72 | 0.72 | 0.72 |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $311.90M | 2.83 | 2.74 | 2.74 | 27.61 |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | N/A | 396.83 | 396.83 | 396.83 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.02
Forward EPS (Est.)
$-1.36
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
